Resistance to Targeted Therapies in Breast Cancer

  • Jenifer R.┬áProsperi

Part of the Resistance to Targeted Anti-Cancer Therapeutics book series (RTACT, volume 16)

Table of contents

  1. Front Matter
    Pages i-xv
  2. Georges E. Tanios, Matthew E. Burow, Bridgette Collins-Burow, David G. Morrison
    Pages 1-34
  3. Dirk Theile, Gal Lenz, Jamil A. Momand, Susan E. Kane
    Pages 35-88
  4. Laura Bourdeanu, Ellen Liu, Suzanne Brint, David Langdon
    Pages 103-116
  5. Remah Ali, Saeed S. Akhand, Michael K. Wendt
    Pages 117-137
  6. Anna T. Lyons, Jenifer R. Prosperi
    Pages 139-154
  7. Ravi Velaga, Masahiro Sugimoto
    Pages 155-178
  8. Back Matter
    Pages 179-184

About this book


We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.



Targeted Therapy Her2-Targeted Therapy Hormone Therapy Angiogenesis EGFR Inhibition

Editors and affiliations

  • Jenifer R.┬áProsperi
    • 1
  1. 1.Harper Cancer Research InstituteUniversity of Notre DameSouth BendUSA

Bibliographic information

  • DOI
  • Copyright Information Springer International Publishing AG 2017
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-3-319-70141-7
  • Online ISBN 978-3-319-70142-4
  • Series Print ISSN 2196-5501
  • Series Online ISSN 2196-551X
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods